Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile CD274 positive
Therapy Retifanlimab
Indication/Tumor Type anal canal squamous cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive anal canal squamous cell carcinoma predicted - sensitive Retifanlimab Phase II Actionable In a Phase II trial (POD1UM-202), Zynyz (retifanlimab) treatment resulted in an objective response rate of 13.8% (13/94, 1 complete response, 12 partial responses), a disease control rate of 48.9%, and a median progression-free survival of 7.4 mo (patients with disease control) in patients with advanced or metastatic anal canal squamous carcinoma, with a significant correlation between tumor PD-L1 (CD274) expression and overall survival (p=0.0088) (PMID: 35816951; NCT03597295). 35816951
PubMed Id Reference Title Details
(35816951) A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). Full reference...